Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. The Californian biopharma ...

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox. From our morning news briefing to a weekly Good News Newsletter, get the ...

Aard­vark Ther­a­peu­tics filed for an IPO Thurs­day night, mak­ing it the sixth biotech in line this year for a po­ten­tial list­ing … ...

Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut. In a 2025 punctuated by news from the weight-loss space, obesity-focused biotech ...

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset Richard Fausset reported ...